April 13 (Reuters) - Bristol-Myers Squibb Co:
* OPDIVO (NIVOLUMAB), FIRST PD-1 INHIBITOR TO DEMONSTRATE SUPERIOR SURVIVAL BENEFIT COMPARED WITH CHEMOTHERAPY IN A PREDOMINANTLY CHINESE POPULATION WITH PREVIOUSLY TREATED NON -SMALL CELL LUNG CANCER (NSCLC)
* IN PHASE 3 CHECKMATE-078 TRIAL, OPDIVO REDUCED RISK OF DEATH BY 32% VERSUS CHEMOTHERAPY
* IN STUDY, OPDIVO DEMONSTRATED A STATISTICALLY SIGNIFICANT BENEFIT VERSUS DOCETAXEL ON PRIMARY ENDPOINT OF OVERALL SURVIVAL
* IN TRIAL, TWO SECONDARY ENDPOINTS OF ORR, MEDIAN DURATION OF RESPONSE DEMONSTRATED DURABILITY WITH OPDIVO VERSUS DOCETAXEL Source text for Eikon: Further company coverage: